

according to Regulation (EC) No. 1907/2006

Desloratadine Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2020
1.12	09.04.2021	778689-00013	Date of first issue: 23.06.2016
SECTION	1: Identification of	of the substance/mi	xture and of the company/undertaking

1.1 Product identifier

Trade name : Desloratadine Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet

Company	:	Organon & Co. Shotton Lane NE23 3JU Cramlington NU - Great Britain
Telephone	:	44 1 670 59 30 00
E-mail address of person responsible for the SDS	:	EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Desloratadine	100643-71-8	Acute Tox. 4; H302	>= 0.025 - <



according to Regulation (EC) No. 1907/2006

Desloratadine Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2020			
1.12	09.04.2021	778689-00013	Date of first issue: 23.06.2016			
			Eye Dam. 1; H318 Repr. 2; H361fd Aquatic Chronic 2; H411	0.1		

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

Protection of first-aiders	:	No special precautions are necessary for first aid responders.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap as a precaution. Get medical attention if symptoms occur.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed None known.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment

: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire- fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides



according to Regulation (EC) No. 1907/2006

Desloratadine Liquid Formulation

Version 1.12	Revision Date: 09.04.2021		DS Number: 8689-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016	
5.3 Advice for firefighters Special protective equipment		:	: Wear self-contained breathing apparatus for firefighting if nec		
	for firefighters Specific extinguishing meth-		 essary. Use personal protective equipment. Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do 		
			so. Evacuate area.		

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

••••••••••••••••••••••••••••••••••••••		
Personal precautions	:	Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

	Clean up remaining materials from spill with suitable absor- bent. Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
--	--

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	:	See Engineering measures under EXPOSURE
		CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Handle in accordance with good industrial hygiene and safety





Desloratadine Liquid Formulation

Version 1.12	Revision Date: 09.04.2021		98 Number: 8689-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016		
Hygiene measures		 practice, based on the results of the workplace exposure assessment Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. 				
7.2 Condi	tions for safe storage,	incl	uding any incom	patibilities		
Requirements for storage areas and containers		:	Keep in properly labelled containers. Store in accordance with the particular national regulations.			
Advice on common storage		:	Do not store with Strong oxidizing a	the following product types: agents		
-	f ic end use(s) ific use(s)	:	No data available			

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Propylene glycol	57-55-6	TWA (particles)	10 mg/m3	GB EH40
			ecific short-term exposure lim	
	figure three til	mes the long-term ex	cposure limit should be used.	
		TWA (Total va-	150 ppm	GB EH40
		pour and parti-	474 mg/m3	
		cles)		
		r information: Where no specific short-term exposure limit is listed, a		
	figure three til	times the long-term exposure limit should be used.		
Desloratadine	100643-71-	TWA	20 µg/m3 (OEB 3)	Internal
	8			
		Wipe limit	200 µg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Propylene glycol	Workers	Inhalation	Long-term local ef- fects	10 mg/m3
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	10 mg/m3
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

according to Regulation (EC) No. 1907/2006



Desloratadine Liquid Formulation

Version 1.12	Revision Date: 09.04.2021	SDS Number: 778689-00013	Date of last issue: 01. Date of first issue: 23.	
Sube	tanco namo	Environment	al Compartment	Value

Substance name	Environmental Compartment	Value
Propylene glycol	Fresh water	260 mg/l
	Marine water	26 mg/l
	Intermittent use/release	183 mg/l
	Sewage treatment plant	20000 mg/l
	Fresh water sediment	572 mg/kg
	Marine sediment	57.2 mg/kg
	Soil	50 mg/kg

8.2 Exposure controls

Engineering measures

Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations.

Personal protective equipr	ent	
Eye protection	: Wear the following personal protective equipment: Safety glasses Equipment should conform to BS EN 166	
Hand protection		
Remarks Skin and body protection Respiratory protection	 Wash hands before breaks and at the end of workday. Skin should be washed after contact. If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the rec- 	
Filter type	ommended guidelines, use respiratory protection. Equipment should conform to BS EN 143 Particulates type (P)	

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance Colour Odour Odour Threshold	:	liquid clear sweet No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling	:	No data available
range Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available

according to Regulation (EC) No. 1907/2006



Desloratadine Liquid Formulation

Version 1.12	Revision Date: 09.04.2021		S Number: 3689-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016
	ver explosion limit / Lower nmability limit	:	No data available	e
Vapour pressure		:	No data available	9
Rel	ative vapour density	:	No data available	9
Rel	ative density	:	No data available	e
De	nsity	:	No data available	e
Par oct Aut Dec Vis	Solubility(ies) Water solubility Partition coefficient: n- octanol/water Auto-ignition temperature Decomposition temperature Viscosity Viscosity, dynamic		soluble No data available No data available No data available	e
	Viscosity, kinematic		No data available	e
Exp	Explosive properties		Not explosive	
Oxidizing properties		:	The substance o	r mixture is not classified as oxidizing.
	er information lecular weight	:	No data available	9
Pai	ticle size	:	No data available	e

SECTION 10: Stability and reactivity

10.1 Reactivity Not classified as a reactivity ha	azar	d.
10.2 Chemical stability Stable under normal conditions	3.	
10.3 Possibility of hazardous read	ctio	ns
Hazardous reactions	:	Can react with strong oxidizing agents.
10.4 Conditions to avoid		
Conditions to avoid	:	None known.
10.5 Incompatible materials Materials to avoid	:	Oxidizing agents

according to Regulation (EC) No. 1907/2006



Desloratadine Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2020
1.12	09.04.2021	778689-00013	Date of first issue: 23.06.2016

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of : Inhalation exposure Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Desloratadine:

Acute oral toxicity

: LD50 (Rat): > 549 mg/kg

LD50 (Mouse): 353 mg/kg

LD50 (Monkey): > 250 mg/kg Symptoms: Vomiting Remarks: No mortality observed at this dose.

Skin corrosion/irritation

Not classified based on available information.

Components:

Desloratadine:

Species	:	Rabbit
Result	:	No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Desloratadine:

Species	:	Rabbit
Remarks	:	Severe eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.





Desloratadine Liquid Formulation

sion 2	Revision Date: 09.04.2021	SDS Number: 778689-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016	
Comp	oonents:			
Desloratadine: Test Type Exposure routes Species Result		: Maximisation 1 : Dermal : Guinea pig : negative	Fest	
	cell mutagenicity assified based on ava	ailable information.		
<u>Comp</u>	oonents:			
Deslo	ratadine:			
Genot	oxicity in vitro	: Test Type: Bao Result: negativ	cterial reverse mutation assay (AMES) /e	
			romosomal aberration łuman lymphocytes /e	
Genot	oxicity in vivo	Species: Mous Cell type: Bone Application Ro	: Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: negative	
Carci	nogenicity			
Not cla	assified based on ava	ailable information.		
Comp	oonents:			
Specie Applic	ation Route sure time	: Mouse : Oral : 2 Years : negative	Oral 2 Years	
LOAE Resul	ation Route L t t Organs	: equivocal : Liver : Based on data The mechanisi	: Oral : 10 mg/kg body weight : equivocal	

Not classified based on available information.

Components:

Desloratadine:

according to Regulation (EC) No. 1907/2006



Desloratadine Liquid Formulation

Effects on fertility: Test Type: Fertility Species: Rat, male Application Route: Oral Fertility: LOAEL: 12 mg/kg body weight Symptoms: Reduced fertility Result: positive Remarks: The mechanism or mode of action may not be relevant in humans.Effects on foetal develop- ment: Test Type: Fertility Species: Rat, female Fertility: LOAEL: 12 mg/kg body weight Symptoms: No effects on fertility Result: negativeEffects on foetal develop- ment: Test Type: Embryo-foetal development Species: Rabit Application Route: Oral Developmental Toxicity: NOAEL: 30 mg/kg body weight Result: No teratogenic effectsEffects on foetal develop- ment: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 9 mg/kg body weight Result: Specific development Symptoms: Viewo-generation toxicly Symptoms: Coale Developmental Toxicity: LOAEL: 18 mg/kg body weight Result: No adverse effectsReproductive toxicity - As- sessment: Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experi- ments.STOT - single exposure:Not classified based on available information.STOT - single exposure	ersion .12	Revision Date: 09.04.2021	SDS Number: 778689-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016
Species: Rat, female Fertility: NOAEL: 3 mg/kg body weight Symptoms: No offects on fertility Result: negativeEffects on foetal develop- ment: Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 30 mg/kg body weight Result: No teratogenic effectsTest Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 9 mg/kg body weight Symptoms: Preimplantation loss, Reduced body weight 	Effects on fertility		Species: Rat, Application Ro Fertility: LOAE Symptoms: Re Result: positiv Remarks: The	male pute: Oral EL: 12 mg/kg body weight educed fertility e mechanism or mode of action may not be rele-
mentSpecies: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 30 mg/kg body weight Result: No teratogenic effectsTest Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 9 mg/kg body weight Symptoms: Preimplantation loss, Reduced body weight Result: Specific developmental abnormalities Remarks: The mechanism or mode of action may not be relevant in humans.Test Type: Two-generation study Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 18 mg/kg body weight Result: No adverse effectsReproductive toxicity - AssessmentSome evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experi- ments.STOT - single exposure Not classified based on available information.			Species: Rat, Fertility: NOAE Symptoms: No	female EL: 3 mg/kg body weight o effects on fertility
Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 9 mg/kg body weight Symptoms: Preimplantation loss, Reduced body weight Result: Specific developmental abnormalities Remarks: The mechanism or mode of action may not be relevant in humans.Test Type: Two-generation study Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 18 mg/kg body weight Result: No adverse effectsReproductive toxicity - As- sessment:Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experi- 		ts on foetal develop-	Species: Rabb Application Ro Developmenta	bit bute: Oral Il Toxicity: NOAEL: 30 mg/kg body weight
Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 18 mg/kg body weight Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on adverse effects on animal experiments. STOT - single exposure Not classified based on available information.			Species: Rat Application Ro Developmenta Symptoms: Pr Result: Specifi Remarks: The	oute: Oral Il Toxicity: LOAEL: 9 mg/kg body weight eimplantation loss, Reduced body weight ic developmental abnormalities mechanism or mode of action may not be rele-
sessment fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments. STOT - single exposure Not classified based on available information.			Species: Rat Application Ro Developmenta	oute: Oral Il Toxicity: LOAEL: 18 mg/kg body weight
Not classified based on available information.	•	•	fertility, based adverse effect	on animal experiments., Some evidence of
			able information	
STOT-TEPERIEU EXPOSUIE		- repeated exposure		

Not classified based on available information.

Repeated dose toxicity

Components:

Desloratadine:

Species	:	Rat
LOAEL	:	30 mg/kg

according to Regulation (EC) No. 1907/2006



Desloratadine Liquid Formulation

ersion 12	Revision Date: 09.04.2021		: issue: 01.10.2020 t issue: 23.06.2016
Expos	cation Route sure time et Organs arks	 Oral 3 Months Kidney Significant toxicity observed in The mechanism or mode of ac mans. 	testing ction may not be relevant in hu
Expos	EL EL cation Route sure time et Organs	 Monkey 6 mg/kg 12 mg/kg Oral 3 Months Central nervous system Gastrointestinal disturbance 	
	EL cation Route sure time	: Monkey : 40 mg/kg : Oral : 17 Months : No significant adverse effects	were reported
	EL cation Route sure time	: Monkey : 6 mg/kg : Oral : 3 Months : Gastrointestinal disturbance, F	Fatigue
•	ation toxicity assified based on ava	ble information.	
Expe	rience with human e	osure	
<u>Comp</u>	oonents:		
Desic	oratadine:		
Inhala Eye c Inges	ontact	 Remarks: May cause respirato Symptoms: Eye irritation Symptoms: dry mouth, muscle sore throat, painful menstration 	pain, Fatigue, Drowsiness,

SECTION 12: Ecological information

12.1 Toxicity

Components:						
Desloratadine:						
Toxicity to fish	:	LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.2 mg/l Exposure time: 96 h Method: FDA 4.11				
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 9.6 mg/l Exposure time: 48 h Method: FDA 4.08				

according to Regulation (EC) No. 1907/2006



Desloratadine Liquid Formulation

Vers 1.12		Revision Date: 09.04.2021	-	98 Number: 8689-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016		
	Toxicity to algae/aquatic plants		:	: EC50 (Pseudokirchneriella subcapitata (green algae)): mg/l Exposure time: 72 h Method: OECD Test Guideline 201			
				NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te			
	Toxicity	to microorganisms	:	EC50 (Natural microorganism): 53.7 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209			
				NOEC (Natural m Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition		
	Toxicity icity)	to fish (Chronic tox-	:	NOEC: 0.12 mg/l Exposure time: 32 Species: Pimepha Method: OECD Te	les promelas (fathead minnow)		
		to daphnia and other invertebrates (Chron- ty)	:	NOEC: 0.48 mg/l Exposure time: 21 Species: Daphnia Method: OECD Te	magna (Water flea)		
12.2	Persist	tence and degradabil	ity				
	Compo	onents:					
		atadine: radability	:	Result: Not readily Biodegradation: 6 Exposure time: 28 Method: OECD Te	67.4 % 3 d		
				Result: Not readily Biodegradation: (Exposure time: 28 Method: FDA 3.11) % 3 d		
	Stability	/ in water	:	Hydrolysis: < 10 % Method: FDA 3.09			
12.3	Bioacc	umulative potential					
	Compo	-					

Components:

Desloratadine:

according to Regulation (EC) No. 1907/2006



Desloratadine Liquid Formulation

Ver: 1.12	sion 2	Revision Date: 09.04.2021		DS Number: 8689-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016		
	Partitio octano	n coefficient: n- l/water	:	log Pow: 1.24 Method: OECD T	est Guideline 107		
12.4	4 Mobili	ty in soil					
	Compo	onents:					
	Distribu	atadine: ution among environ- compartments	:	log Koc: 3.00 Method: OECD T	est Guideline 106		
12.5	5 Result	s of PBT and vPvB a	sse	ssment			
	Produ	ct:					
	Assess		:	to be either persis	ixture contains no components considered stent, bioaccumulative and toxic (PBT), or id very bioaccumulative (vPvB) at levels of		
12.6	6 Other	adverse effects					
	Produ	ct:					
		ine disrupting poten-	:	ered to have endo REACH Article 57	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.		
SE	SECTION 13: Disposal considerations						
13.1	l Waste	treatment methods					
	Droduc			Dispose of in acc	ordance with local regulations		

Product		Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in
Contaminated packaging	:	discussion with the waste disposal authorities. Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

Not regulated as a dangerous good

14.2 UN proper shipping name

Not regulated as a dangerous good

14.3 Transport hazard class(es)

Not regulated as a dangerous good

according to Regulation (EC) No. 1907/2006



Desloratadine Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2020
1.12	09.04.2021	778689-00013	Date of first issue: 23.06.2016

14.4 Packing group

Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on		Not applicable
the market and use of certain dangerous substances,	•	Not applicable
preparations and articles (Annex XVII)		
		Not oppliaable
REACH - Candidate List of Substances of Very High	•	Not applicable
Concern for Authorisation (Article 59).		
REACH - List of substances subject to authorisation	:	Not applicable
(Annex XIV)		
Regulation (EC) No 1005/2009 on substances that de-	:	Not applicable
plete the ozone layer		
Regulation (EU) 2019/1021 on persistent organic pollu-	:	Not applicable
tants (recast)		
Regulation (EC) No 649/2012 of the European Parlia-	:	Not applicable
ment and the Council concerning the export and import	•	
e 1 1		
of dangerous chemicals		
Severa III: Directive 2012/18/ELL of the European Parlian	nent	and of the Council (

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances. Not applicable

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL		not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements		
H302	:	Harmful if swallowed.

according to Regulation (EC) No. 1907/2006

Desloratadine Liquid Formulation

Version 1.12	Revision Date: 09.04.2021		DS Number: 8689-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016	
H318 H361fd		:	Causes serious eye damage.Suspected of damaging fertility. Suspected of damaging the unborn child.		
H411		:	: Toxic to aquatic life with long lasting effects.		
Full text of other abbrevia		ons			
Acute ⁻	Гох.	:	Acute toxicity		
Aquatic Chronic		:	Long-term (chronic) aquatic hazard		
Eye Dam.		:	Serious eye damage		
Repr.		:	Reproductive toxicity		
GB EH40		:	UK. EH40 WEL - Workplace Exposure Limits		
GB EH40 / TWA		:	Long-term exposu	ure limit (8-hour TWA reference period)	

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization: KECI - Korea Existing Chemicals Inventory: LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only



according to Regulation (EC) No. 1907/2006

Desloratadine Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2020
1.12	09.04.2021	778689-00013	Date of first issue: 23.06.2016

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN